膀胱癌根治性膀胱切除术中扩大与局限淋巴结清扫的生存结果:前瞻性随机试验
这项前瞻性多中心III期随机试验纳入401例T1G3或肌层浸润性膀胱尿路上皮癌患者,比较扩大与局限淋巴结清扫对无复发生存的影响。结果显示扩大清扫在无复发生存、癌症特异性生存和总生存上均未显著优于局限清扫,且扩大组Clavien≥3级淋巴囊肿更常见。
要点
- 扩大淋巴结清扫未显著改善无复发生存(5年RFS 65% vs 59%,HR=0.84,p=0.36)。
- 癌症特异性生存和总生存亦无显著差异(5年CSS 76% vs 65%,p=0.10;5年OS 59% vs 50%,p=0.12)。
- 扩大清扫组术后90天内Clavien≥3级淋巴囊肿报告更频繁。
核心结论
- 扩大淋巴结清扫在无复发生存、癌症特异性生存和总生存方面未显示出显著优于局限淋巴结清扫。
- 需要更大规模试验来确定扩大清扫是否带来小幅但有临床意义的生存差异。
研究设计与样本
- 前瞻性、多中心、III期随机试验,纳入局部可切除的T1G3或肌层浸润性膀胱尿路上皮癌(T2-T4aM0)患者。
- 2006年2月至2010年8月共随机401例患者,局限清扫组203例,扩大清扫组198例。
- 主要终点为无复发生存,次要终点包括癌症特异性生存、总生存和并发症;试验设计预期扩大清扫组5年RFS提高15%。
主要发现
- 局限清扫组中位清扫淋巴结数为19枚,扩大清扫组为31枚。
- 5年无复发生存率扩大组65% vs 局限组59%(HR=0.84,95%CI 0.58-1.22,p=0.36)。
- 5年癌症特异性生存率扩大组76% vs 局限组65%(HR=0.70,p=0.10)。
- 5年总生存率扩大组59% vs 局限组50%(HR=0.78,p=0.12)。
- 扩大清扫组术后90天内Clavien≥3级淋巴囊肿报告更频繁;纳入T1G3肿瘤可能 contributed to 阴性结果。
临床怎么用
- 对于接受根治性膀胱切除术的膀胱癌患者,扩大淋巴结清扫未显示生存优势,临床决策需权衡其并发症风险。
- 扩大清扫组Clavien≥3级淋巴囊肿更常见,术后需关注淋巴囊肿相关并发症。
局限性
- 纳入T1G3肿瘤可能 contributed to 阴性研究结果。
- 样本量可能不足以检测小幅但有临床意义的生存差异,需要更大规模试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extent of lymph node dissection (LND) in bladder cancer (BCa) patients at the time of radical cystectomy may affect oncologic outcome. OBJECTIVE: To evaluate whether extended versus limited LND prolongs recurrence-free survival (RFS). DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter, phase-III trial patients with locally resectable T1G3 or muscle-invasive urothelial BCa (T2-T4aM0). INTERVENTION: Randomization to limited (obturator, and internal and external iliac nodes) versus extended LND (in addition, deep obturator, common iliac, presacral, paracaval, interaortocaval, and para-aortal nodes up to the inferior mesenteric artery). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was RFS. Secondary endpoints included cancer-specific survival (CSS), overall survival (OS), and complications. The trial was designed to show 15% advantage of 5-yr RFS by extended LND. RESULTS AND LIMITATIONS: In total, 401 patients were randomized from February 2006 to August 2010 (203 limited, 198 extended). The median number of dissected nodes was 19 in the limited and 31 in the extended arm. Extended LND failed to show superiority over limited LND with regard to RFS (5-yr RFS 65% vs 59%; hazard ratio [HR]=0.84 [95% confidence interval 0.58-1.22]; p=0.36), CSS (5-yr CSS 76% vs 65%; HR=0.70; p=0.10), and OS (5-yr OS 59% vs 50%; HR=0.78; p=0.12). Clavien grade ≥3 lymphoceles were more frequently reported in the extended LND group within 90d after surgery. Inclusion of T1G3 tumors may have contributed to the negative study result. CONCLUSIONS: Extended LND failed to show a significant advantage over limited LND in RFS, CSS, and OS. A larger trial is required to determine whether extended compared with limited LND leads to a small, but clinically relevant, survival difference (ClinicalTrials.gov NCT01215071). PATIENT SUMMARY: In this study, we investigated the outcome in bladder cancer patients undergoing cystectomy based on the anatomic extent of lymph node resection. We found that extended removal of lymph nodes did not reduce the rate of tumor recurrence in the expected range.
引用
- Gschwend JE, Heck MM, Lehmann J, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol. 2018. PMID: 30337060. doi:10.1016/j.eururo.2018.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。